Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En fas III-studie för att bedöma säkerheten och immunogeniciteten hos en HIPRAs kandidatboostervaccination mot covid-19.

12 november 2026 uppdaterad av: Hipra Scientific, S.L.U

En fas III, öppen etikett, enkelarm, multicenter, försök för att bedöma säkerheten och immunogeniciteten hos en boostervaccination med en rekombinant protein RBD Fusion heterodimerkandidat (PHH-1V) mot SARS-CoV-2, hos vuxna vaccinerade mot covid -19.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.

Studietyp

Interventionell

Inskrivning (Faktisk)

2661

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Milano
      • Milan, Milano, Italien, 20162
        • Hospital de Niguarda
    • BARCELONA
      • Badalona, BARCELONA, Spanien, 08916
        • Hospital Germans Trias I Pujol
      • Barcelona, BARCELONA, Spanien, 08035
        • Hospital Vall Hebron
    • Barcelona
      • Barcelona, Barcelona, Spanien, 08023
        • Hospital HM Delfos
      • Barcelona, Barcelona, Spanien, 08023
        • Hospital Quironsalud Barcelona
      • Mollet del Vallès, Barcelona, Spanien, 08100
        • Hospital de Mollet
    • Girona
      • Girona, Girona, Spanien, 17007
        • Hospital Universitari Dr. Josep Trueta
    • Madrid
      • Madrid, Madrid, Spanien, 28046
        • Hospital Universitario La Paz
      • Madrid, Madrid, Spanien, 28007
        • Hospital Gregorio Marañón
      • Madrid, Madrid, Spanien, 28050
        • Hospital HM Sanchinarro
      • Madrid, Madrid, Spanien, 28660
        • Hospital HM Montepríncipe
      • Madrid, Madrid, Spanien, 28223
        • Hospital Quironsalud Madrid
      • Meco, Madrid, Spanien, 28805
        • Hospital Principe de Asturias
      • Móstoles, Madrid, Spanien, 28938
        • Hospital HM Puerta del Sur
    • Málaga
      • Málaga, Málaga, Spanien, 29010
        • Hospital Regional Universitario de Málaga
    • Spain
      • Barcelona, Spain, Spanien, 17170
        • Hospital Clinic de Barcelona
    • VIZCAYA
      • Barakaldo, VIZCAYA, Spanien, 48903
        • Hospital de Cruces
    • Valencia
      • Valencia, Valencia, Spanien, 46010
        • Hospital Clínico de Valencia

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

16 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Male or female, ≥ 16 years old at Day 0.
  • Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
  • Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
  • If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
  • Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
  • Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
  • Female participant of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
  • Female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
  • Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
  • Male participants must refrain from donating sperm for at least 28 days after day 0.

Exclusion Criteria:

  • History of anaphylaxis to any prior vaccine.
  • Previous severe SARS-CoV-2 infections that required >24 hous of hospitalisation.
  • Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
  • Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
  • Having a clinically significant acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
  • Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
  • Having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
  • Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
  • Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
  • Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
  • Having abnormal function of the immune system, except stable clinical conditions like controlled HIV.
  • Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
  • Chronic or recurrent administration of systemic immunosuppressant medication.
  • Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
  • Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
  • Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
  • Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
  • Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Experimental: COVID-19 Vaccine HIPRA 40 ug/dose

COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA

Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Tidsram: Day 7

Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.

Day 7
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)
Tidsram: Day 28

Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination

Day 28
Incidence of Serious Adverse Events (Safety and tolerability) (SAE)
Tidsram: Day 365

Number and percentage of serious adverse events (SAEs) through the end of the study.

Day 365
Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).
Tidsram: Day 365

Number and percentage of adverse event of special interest (AESI) through the end of the study.

Day 365
Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)
Tidsram: Day 365

Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the end of the study.

Day 365
Incidence of Adverse Events in laboratory parameters (Safety and tolerability)
Tidsram: Day 365

Grade 3 and 4 changes from baseline in safety laboratory parameters at Days 14, 91 and 182 after vaccination.

through the end of the study.

Day 365

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in the immunogenicity measured by pseudovirus neutralisation
Tidsram: Day 365

Neutralisation titre against Wuhan and Omicron strains, and any other relevant VOC in the epidemiologic moment, measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for descriptive statistics analysis at Baseline and at Days 14, 91, 182 and 365.

Day 365
Changes in the immunogenicity measured by pseudovirus neutralisation
Tidsram: Day 14

The geometric mean fold rise (GMFR) in neutralising antibody titre from baseline to Day 14.

Day 14
Changes in the immunogenicity measured by means of total antibody against RBD
Tidsram: Day 365

Binding antibodies titre measured for each individual sample and GMT for descriptive statistics analysis at Baseline and Days 14, 91, 182 and 365.

Day 365
Changes in the immunogenicity measured by means of total antibody against RBD.
Tidsram: Day 14

The geometric mean fold rise (GMFR) in binding antibody titre from baseline to Day 14.

Day 14
Changes in the immunogenicity measured by means of total antibody against RBD
Tidsram: Day 14

The percentage of subjects that after the booster dose have a ≥4-fold change in binding antibodies titre from Baseline to Day 14.

Day 14

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To assess number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Tidsram: Day 365

Number and percentage of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster according to COVID-19 infection criteria throughout the study duration.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Tidsram: Day 365

Number and percentage of COVID-19 severe infections ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V and hospital admissions SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Tidsram: Day 365

Number and percentage of hospital admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V in ICU. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Tidsram: Day 365

Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V receiving noninvasive ventilation. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Tidsram: Day 365

Number and percentage of noninvasive ventilation administration associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V causing death.
Tidsram: Day 365

Number and percentage of deaths associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To evaluate T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster..
Tidsram: Day 14

T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole peripheral blood mononuclear cell (PBMC) stimulation by enzyme-linked immune absorbent spot (ELISpot) at Baseline and at Day 14. This analysis will be performed in 30 subjects.

Day 14
To assess Th-1/Th-2 T-cell mediated responses against S protein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster.
Tidsram: Day 14

CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at Baseline and at Day 14. This analysis will be performed in 30 subjects.

Day 14

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Teresa Prat, HIPRA SICENTIFIC S.L.U

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 februari 2022

Primärt slutförande (Faktisk)

3 mars 2023

Avslutad studie (Faktisk)

3 mars 2023

Studieregistreringsdatum

Först inskickad

8 februari 2022

Först inskickad som uppfyllde QC-kriterierna

17 februari 2022

Första postat (Faktisk)

18 februari 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera